Nanobodies- combining the advantages of antibody drugs with the features of small-molecule drugs.




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Nanobodies- combining the advantages of antibody drugs with the features of small-molecule drugs.
Released on: February 20, 2015. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Ablynx is engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonology.
  • Summary
  • Transcript
  • Participants
  • Company
Ablynx is engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonology. During Biotech and Money London Edwin Moses, CEO, Ablynx explains their classic hybrid business model to Fintan Walton.
Ablynx is engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonology. During Biotech and Money London Edwin Moses, CEO, Ablynx explains their classic hybrid business model to Fintan Walton.
Edwin Moses
Ablynx
Ablynx NV